Ewing’s U: New PEEL-224 Phase I/II Clinical Trial

Ewing's U
Written By Alana Arens

Dr. David Shulman (Dana Farber Cancer Institute) discusses the newly opened PEEL-224 Phase I/II Clinic Trial (NCT06709495) for relapse or refractory sarcomas in AYAs. PEEL-224 is newly formulated Topoisomerase I Inhibitor with preclinical efficacy as a single agent. For this clinical trial, PEEL-224 will combined with Vincristine and Temozolomide (V, P, T).

Alana Arens
Previous

GRANT: Aptadel Therapeutics (España) - $500,000
Next

SupraVax: Cleveland Clinic Ewing Sarcoma Vaccine Trial Update